Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$27.17 - $31.97 $336,364 - $395,788
-12,380 Reduced 51.56%
11,631 $326,000
Q2 2023

Jul 27, 2023

BUY
$28.34 - $33.63 $680,471 - $807,489
24,011 New
24,011 $752,000
Q2 2022

Aug 09, 2022

SELL
$26.4 - $30.54 $502,946 - $581,817
-19,051 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$23.07 - $27.99 $439,506 - $533,237
19,051 New
19,051 $501,000
Q2 2021

Sep 17, 2021

SELL
$18.78 - $25.15 $217,735 - $291,589
-11,594 Closed
0 $0
Q1 2021

May 19, 2021

SELL
$18.21 - $23.2 $298,407 - $380,178
-16,387 Reduced 58.56%
11,594 $217,000
Q4 2020

Feb 24, 2021

BUY
$15.39 - $22.1 $209,950 - $301,488
13,642 Added 95.14%
27,981 $558,000
Q3 2020

Dec 11, 2020

BUY
$16.16 - $20.66 $231,718 - $296,243
14,339 New
14,339 $238,000
Q4 2019

Feb 04, 2020

SELL
$17.29 - $21.74 $186,541 - $234,552
-10,789 Closed
0 $0
Q3 2019

Nov 20, 2019

BUY
$19.51 - $24.28 $210,493 - $261,956
10,789 New
10,789 $210,000
Q2 2019

Aug 13, 2019

SELL
$21.47 - $37.33 $225,392 - $391,890
-10,498 Closed
0 $0
Q1 2019

Apr 12, 2019

SELL
$28.4 - $36.49 $124,761 - $160,300
-4,393 Reduced 29.5%
10,498 $383,000
Q4 2018

Jan 16, 2019

BUY
$27.94 - $44.61 $260,261 - $415,542
9,315 Added 167.06%
14,891 $439,000
Q3 2018

Nov 13, 2018

SELL
$38.6 - $46.12 $215,233 - $257,165
-5,576 Reduced 50.0%
5,576 $237,000
Q3 2018

Nov 13, 2018

SELL
$38.6 - $46.12 $24,781 - $29,609
-642 Reduced 5.44%
11,152 $327,000
Q1 2018

May 14, 2018

BUY
$53.61 - $67.26 $632,276 - $793,264
11,794 New
11,794 $684,000
Q4 2017

Feb 09, 2018

SELL
$47.69 - $55.39 $188,518 - $218,956
-3,953 Closed
0 $0
Q3 2017

Nov 15, 2017

BUY
$49.16 - $54.45 $194,329 - $215,240
3,953
3,953 $201,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $5.14B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.